| Literature DB >> 34159143 |
Syawal Abdurrahman1,2, Ruslin Ruslin3, Aliya Nur Hasanah1, Resmi Mustarichie1.
Abstract
Alopecia is a condition in which some or all of the hair from the scalp is lost. One recent preventative measure is the inhibition of the enzyme 5-α-reductase. Inhibition of the enzyme 5-α-reductase converts circulating testosterone to its more potent metabolite, dihydrotestosterone. Ethnobotically, Merremia peltata is used as a baldness medicine by utilising compounds contained within the leaves. This research aimed to test activity of 18 known compounds contained within M. peltata) as anti-alopecia. Activity was based on their interaction with the androgen receptor (PDB code 4K7a) using molecular docking and ADME-Tox prediction. The stages of research performed were: preparation of androgen protein structure databases; preparation and optimization of three-dimensional structures of compounds using ChemDraw 8.0; molecular docking to the androgen receptor protein using Autodock 1.5.6.; and ADME-Tox prediction using the pkCSM tool. The following test compounds had strong bond energies (ΔG): compound 16 (olean-12-en-3beta-ol, cinnamate)-7.71 kcal/mol, compound 17 (alpha-amyrine)-6.34 kcal/mol, and Finasteride-6.03 kcal/mol. Interestingly, the ΔG of compound 16 (olean-12-en-3beta-ol, cinnamate) is better than of minoxidil (-4.8 kcal/mol) and also to gold-standard treatment compound, finasteride. ADME-Tox prediction for compound 16 showed favorable results in several metrics such as skin permeability, absorption, and distribution. Compound 16 (olean-12-en-3beta-ol, cinnamate) is therefore a potential androgen receptor antagonist and may be beneficial in the treatment of alopecia. Copyright:Entities:
Keywords: ADME-Tox; Merremia peltata; alopecia; enzyme 5-α-reductase; molecular docking
Year: 2021 PMID: 34159143 PMCID: PMC8177154 DOI: 10.4103/japtr.JAPTR_222_20
Source DB: PubMed Journal: J Adv Pharm Technol Res ISSN: 0976-2094
Figure 1Androgen receptor (46Ka)
Two-dimensional structures of minoxidil, finasteride and test ligands derived from the leaves of Merremia peltata
| Structure | IUPAC name |
|---|---|
| Compound 1 neophytadiene | |
| Compound 2 icosone | |
| Compound 3 isophytol | |
| Compound 4 hexadecaneoic acid-ethyl ester | |
| Compound 5 hexadecaneoic acid | |
| Compound 6 oleyl alcohol | |
| Compound 7 L-heptadecene | |
| Compound 8 (E)-3,7,11,15-tetramethylhexadec-2-en-1-ol | |
| Compound 9 (Z)-9-tricosene | |
| Compound 10 squalene | |
| Compound 11 heneicosane | |
| Compound 12 octyl heptadecane | |
| Compound 13 vitamin E | |
| Compound 14 octacosane | |
| Compound 15 11-eecyldocosane | |
| Compound 16 olean-12-en-3beta-ol, cinnamate | |
| Compound 17 alpha-amyrine | |
| Compound 18 friedeline | |
| Reference ligand Finasteride | |
| Natural ligand minoxidil |
IUPAC: International union of pure and applied chemistry
Figure 2Structure of (a) the androgen receptor (4K7a) and (b) minoxidil which has been separated from its receptor
Figure 3Overlay of docked pose of minoxidil with that of the co-crystallized ligand of 4K7A
Validation results for the molecular docking method
| Protein | Compound | Binding energy (kcal/mol) | RMSD | Hydrogen bond distance (Ǻ) | Amino acids that bind | Nearest residues |
|---|---|---|---|---|---|---|
| 4K7A | Minoxidil | -4.8 | 2.31 | 2.28 and 2.90 | SER865 and GLU793 | LEU862, LYS861, TYR857 |
RMSD: Root-mean-square deviation
Figure 4Visualisation of interactions between minoxidil and androgen receptors (4K7A). Hydrogen bonds are represented by green bonds, minoxidil is represented by grey structures
Figure 5Overlay of the docked poses of the test compounds on that of minoxidil
Docking simulation results
| Compound | Binding energy (kcal/mol) | Hydrogen bond distance (Ǻ) | Hydrogen bonds | Nearest amino acid residue(s) |
|---|---|---|---|---|
| Minoxidil | −4.8 | 2.28 and 2.90 | SER865 and GLU793 | LEU862, LYS861, TYR857 |
| Finasteride | −6.03 | 2.86, 1.88 and 2.13 | ARG854, GLU793 and SER865 | LYS861, LUE797 |
| Compound 1 | −3,97 | - | - | LEU797, LYS861, LEU862 ILE869, HIS789 |
| Compound 2 | −2.89 | - | - | PRO868, TYR857, ARG854 |
| Compound 3 | −3.08 | 2.05 and 1.96 | GLU793 and HIS789 | PRO868, LYS861, TRP796, LUE797, LUE862 |
| Compound 4 | −2.36 | 1.86 | VAL854 | LYS861 |
| Compound 5 | −3.4 | 1.74 | ARG854 | - |
| Compound 6 | −2.25 | 1.76 | LYS861 | - |
| Compound 7 | −2.67 | - | - | TYR857, ARG854 |
| Compound 8 | −3.01 | 1.87 | GLU793 | LYS861, TRP796, LUE797, HIS789 |
| Compound 9 | −1.74 | - | - | TRP796 |
| Compound 10 | −3.3 | - | - | LUE797, LUE862, LYS861, TYR857 |
| Compound 11 | −2.05 | - | - | LYS861, HIS789 |
| Compound 12 | −2.21 | - | - | TYR857, ARG854, LYS861, TRP796 |
| Compound 13 | −4.72 | 2.09 | SER865 | LUE862, LYS861, TRP796, LUE797, HIS789 |
| Compound 14 | −0.24 | - | - | ARG854, TRP796 |
| Compound 15 | −0.96 | - | - | LUE797 |
| Compound 16 | −7.71 | 2.43 | SER865 | LYS861, TRP796, LUE797 |
| Compound 17 | −6.34 | - | - | LYS861, TRP796, LUE797 |
| Compound 18 | −6.17 | - | - | TYR857, TRP796, LUE797 |
Figure 6Visualisation of molecular docking between the androgen receptor and (a) finasteride and (b) compound 16 (olean-12-en-3beta-ol, cinnamate)
Absorption and distribution prediction values
| Compound | Absorption | Distribution | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Minoxidil | −2.871 | 0.653 | 94.641 | −2.798 | 0.142 | 0.773 | −0.951 | −3.471 |
| Finasteride | −5.148 | 1.269 | 93.742 | −3.463 | −0.185 | 0.01 | −0.18 | −1.821 |
| Compound 16 | − 5.772 | 1.475 | 95.733 | − 2.692 | 0.09 | 0 | 0.334 | −1.267 |
Model name and unit: 1: Water solubility (log mol/L), 2: Caco2 permeability (log Papp in 10−6 cm/s), 3: Intestinal absorption (human) ([% Absorbed]), 4: Skin permeability ([log Kp]), 5: Vdss (human) ([log L/kg]), 6: Fraction unbound (human) ([Fu]), 7: BBB permeability ([log BB]), 8: CNS permeability ([log PS])
Metabolism, excretion and toxicity prediction results
| Compound | Metabolism | Excretion | Toxicity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
| Minoxidil | No | No | 0.275 | No | −0.359 | No | No | 2.286 | Yes | No | 3.516 |
| Finasteride | Yes | Yes | 0.38 | No | −1.355 | No | No | 2.424 | Yes | No | 0.638 |
| Compound 16 | Yes | No | −0.294 | No | 0.672 | No | Yes | 2.718 | No | No | −3.596 |
Model name and unit: 9: CYP3A4 substrate ( [Yes/No]), 10: CYP2C9 inhibitor ([Yes/No]), 11: Total clearance ( [log ml/min/kg]), 12: AMES toxicity ( [Yes/No]), 13: Maximum tolerated dose (human) ([log mg/kg/day]), 14: hERG I inhibitor ([Yes/No]), 15: hERG II inhibitor ([Yes/No]), 16: Oral rat acute toxicity (LD50) ( [mol/kg]), 17: Hepatotoxicity ([Yes/No]), 18: Skin sensitisation ([Yes/No]), 19: Minnow toxicity ([log mM])